Abstract:Activating mutations in RAS are found in approximately 30% of human cancers, resulting in the delivery of a persistent signal to critical downstream effectors that drive tumorigenesis. RAS-driven malignancies respond poorly to conventional cancer treatments and inhibitors that target RAS directly are limited; therefore, the identification of new strategies and/or drugs to disrupt RAS signaling in tumor cells remains a pressing therapeutic need. Taking advantage of the live-cell bioluminescence resonance energy transfer (BRET) methodology, we describe the development of a NanoBRET screening platform to identify compounds that modulate binding between activated KRAS and the CRAF kinase, an essential effector of RAS that initiates ERK cascade signaling. Using this strategy, libraries containing synthetic compounds, targeted inhibitors, purified natural products, and natural product extracts were evaluated. These efforts resulted in the identification of compounds that inhibit RAS/RAF binding and in turn suppress RAS-driven ERK activation, but also compounds that have the deleterious effect of enhancing the interaction to upregulate pathway signaling. Among the inhibitor hits identified, the majority were compounds derived from natural products, including ones reported to alter KRAS nanoclustering (ophiobolin A), to impact RAF function (HSP90 inhibitors and ROS inducers) as well as some with unknown targets and activities. These findings demonstrate the potential for this screening platform in natural product drug discovery and in the development of new therapeutic agents to target dysregulated RAS signaling in human disease states such as cancer.

Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution

Single-cell sensor analyses reveal signaling programs enabling Ras-G12C drug resistance

Noninvasive Imaging of Ras Activity by Monomolecular Biosensor Based on Split-Luciferase Complementary Assay

Fluorescent Biosensor for Measuring Ras Activity in Living Cells

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions

Recombinant biosensors for multiplex and super-resolution imaging of phosphoinositides

design of Ras isoform selective binders

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

Cell-based optimization and characterization of genetically encoded location-based biosensors for Cdc42 or Rac activity

Exploring the state- and allele-specific conformational landscapes of Ras: understanding their respective druggabilities

Proteomic Sensors for Quantitative, Multiplexed and Spatial Monitoring of Kinase Signaling

Bifunctional Small Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins

Subcellular Resolution Mapping of Endogenous Cytokine Secretion by Nano-Plasmonic-Resonator Sensor Array

Nanoscopic Spatial Association between Ras and Phosphatidylserine on the Cell Membrane Studied with Multicolor Super Resolution Microscopy

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

Spatiotemporally Resolved Protein Detection in Live Cells Using Nanopore Biosensors

Ras signaling mechanisms: New insights from single-molecule biophysics

Single molecule Lipid Biosensors Mitigate Inhibition of Endogenous Effector Proteins

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS2

Real-Time Imaging of Rab5 Activity Using A Prequenched Biosensor

Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction